Business
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
– Reported ECOSPOR III Phase 3 study of SER-109 met primary endpoint, demonstrated statistically significant absolute reduction of 30.2% in rate of C.
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\n– Reported ECOSPOR III Phase 3 study of SER-109 met primary endpoint, demonstrated statistically significant absolute reduction of 30.2% in rate of C. difficile infection recurrence compared to placebo –\n\n– SER-109 anticipated to be first-ever FDA-approved microbiome therapy –\n\n– First patient dosed in SER-301 Phase 1b study in mild-to-moderate ulcerative colitis –\n\n– Strengthened balance sheet with $264 million financing to support R&D and CMC capabilities expansion, ongoing clinical studies, and pre-commercial launch activities –\n\n– Conference call at 8:30 a.m. ET today –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc., (Nasdaq: MCRB) today reported financial results from the third quarter ended September 30, 2020, and provided business updates.\n\n“Supported by our positive, highly significant SER-109 Phase 3 results, we expect SER-109 to be the first-ever microbiome therapy approved by the U.S. FDA. Following those remarkable SER-109 study data and a significant capital infusion, Seres is in the midst of transformational growth toward becoming a commercial-stage microbiome company, with a broad portfolio of promising therapeutic candidates. We are expanding our field-leading capabilities across R&D, manufacturing, and commercial operations to maximize the multitude of opportunities we see for our approach,” said Eric Shaff, President and Chief Executive Officer of Seres. “Our immediate priorities are to drive enrollment in our SER-109 open-label study to fulfill our safety database requirements and prepare to file a Biologics License Application (BLA), while also preparing the Company for the potential commercialization of SER-109.”\n\n“In tandem, we continue to advance our deep microbiome pipeline, including SER-287, SER-301, SER-401, and SER-155. These therapeutic candidates span infectious diseases, inflammatory disease, and cancer, and we believe all have the potential to fundamentally improve upon the current standard of care. Most recently, we were pleased to dose the first subject in our SER-301 Phase 1b study in patients with ulcerative colitis. Moving forward, we expect to reach a number of value-creating milestones across multiple therapeutic areas,” concluded Mr. Shaff.\n\nProgram and Corporate Updates\n\nSER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection: SER-109 is ...